Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

Inflammation cuts both ways

Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder.

6 Apr 2006

Immune response protects against brain tumor development

In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.

4 Apr 2006

Gene therapy treatment for brain tumours and infections

In a study published in the March 15 issue of The Journal of Immunology, researchers at Board of Governors' Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have developed a way to overcome immune privilege in the brain to eradicate potentially deadly brain tumors such as glioblastoma multiforme and other types of brain infections.

27 Mar 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

Target identified for therapeutic drugs to fight adult brain cancer

A research team at UT Southwestern Medical Center has discovered a cell-signaling mechanism instrumental in the most common brain cancer in adults.

16 Jan 2006

Study suggests a way to eliminate glioblastoma

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM).

7 Dec 2005

Researchers can now identify patients likely to respond to cancer drug therapy

Researchers at UCLA's Jonsson Cancer have identified key characteristics in certain deadly brain tumors that make them 51 times more likely to respond to a specific class of drugs than tumors in which the molecular signature is absent.

13 Nov 2005

Combination of radiotherapy and a drug named S247 as a cure for cancer

Does a combination of radiation therapy and the inhibition of integrins (key molecules in angiogenesis) improve the chance of cure in cancer?

3 Nov 2005

EphA2 represents a promising treatment target for glioblastoma multiforme

Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.

1 Nov 2005

Researchers at Johns Hopkins have identified three new genetic mutations in brain tumors

...a discovery that could pave the way for more effective cancer treatments.

27 Sep 2005

Mutations in receptor tyrosine kinases provide potential for highly-targeted cancer therapies

Scientists from J. Craig Venter Institute, Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.

26 Sep 2005

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.

15 Aug 2005

Asthma may be linked to a decreased risk of brain cancer

According to new research there is a suggestion that gene variants known to raise the risk of asthma, might also decrease the risk of a common type of brain cancer that progresses rapidly and is fatal.

18 Jul 2005

Having asthma, hay fever or another allergic condition may reduce the risk of developing Glioblastoma multiforme

Glioblastoma multiforme (GBM) affects three out of 100,000 people, a rate that quadruples to 13 out 100,000 among people who are 65 and older. The average five-year survival rate from the time of diagnosis for GBM is only 3.3 percent, and is lower for people 65 and older.

15 Jul 2005

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

Chemotherapy for brain tumors is boosted after vaccine targets resistance-related TRP-2 antigen

In the August issue of the journal Oncogene, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute describe a molecular mechanism that appears to make malignant brain tumors more vulnerable to chemotherapy after they have been treated with the dendritic cell vaccine.

13 Jun 2005

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.

10 Jun 2005